Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30269530 | 1.00 | ACSS2 (0.42) | ACSS2KDM4EDRD2TBXA2RIDH1 | |
| SCHEMBL27110991 | 0.86 | ACSS2 (0.41) | ACSS2KDM4EDRD2TBXA2RIDH1 | |
| SCHEMBL30269574 | 0.86 | ACSS2 (0.41) | ACSS2KDM4EDRD2TBXA2RIDH1 | |
| SCHEMBL29149830 | 0.84 | ACSS2 (0.44) | ACSS2KDM4EDRD2TBXA2RIDH1 | |
| SCHEMBL29664315 | 0.84 | ACSS2 (0.44) | ACSS2KDM4EDRD2TBXA2RIDH1 | |
| SCHEMBL23363441 | 0.84 | ACSS2 (0.44) | ACSS2KDM4EDRD2TBXA2RIDH1 | |
| SCHEMBL29924345 | 0.84 | ACSS2 (0.44) | ACSS2KDM4EDRD2TBXA2RIDH1 | |
| SCHEMBL25340969 | 0.83 | ACSS2 (0.44) | ACSS2KDM4EDRD2TBXA2RIDH1 | |
| SCHEMBL29555279 | 0.83 | ACSS2 (0.44) | ACSS2KDM4EDRD2TBXA2RIDH1 | |
| SCHEMBL30269560 | 0.83 | DCTPP1 (0.33) | ACSS2KDM4EDRD2TBXA2RALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023164050-A1 | COMPOUNDS AS GLP-1R AGONISTS | TERNS PHARMACEUTICALS, INC. (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023138684-A1 | HETEROCYCLIC GLP-1 AGONISTS | GASHERBRUM BIO , INC. (US) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322758-A1 | COMPOUNDS AS GLP-1R AGONISTS | GLP1R, GIPR, GCGR | ACSS2 1527/4885KDM4E 4310/4885DRD2 3615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.